UCAR T-cell therapy targeting CD19 and BCMA
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for UCAR T-cell therapy targeting CD19 and BCMA, covering 2025-12-15 to 2025-12-15. Get the full timeline:
Most recent: Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases [EARLY_Phase 1]